{
	"kihkd7orText": "P<span class=\"_ _1\"></span>ersp<span class=\"_ _1\"></span>ec<span class=\"_ _4\"></span>tiv<span class=\"_ _1\"></span>e on the ef<span class=\"_ _4\"></span>fica<span class=\"_ _1\"></span>c<span class=\"_ _4\"></span>y and a<span class=\"_ _0\"></span>cc<span class=\"_ _1\"></span>epta<span class=\"_ _1\"></span>bil<span class=\"_ _1\"></span>it<span class=\"_ _4\"></span>y <br><span class=\"ls5b ws7f\">of<span class=\"_ _4\"></span> Brin<span class=\"_ _4\"></span>tellix®*</span><span class=\"fs3 v1\">1</span>",
	"kihkd7osText": "Study Design",
	"kihkd7otText": "Head-to-head studies only",
	"kihkd7ouText": "Acceptability (OR)",
	"kihkd7ovText": "Efficacy (OR)",
	"kihkd7owText": "Brintellix®",
	"kihkd7oxText": "522 trials, 116,477 pa<span class=\"_ _1\"></span>tients and 21 antidepressants were analyzed in the acute tre<span class=\"_ _1\"></span>atment of<span class=\"_ _4\"></span> adults with <br>major depressive disorder",
	"kihkd7oyText": "Zoom",
	"Brintellix_26dd9baeba": "<span style=\"font-family: &quot;1_WUORLG+AvenirNextLTPro-Bold&quot;; color: rgb(77, 127, 134);\"><font style=\"font-size: 23px;\">\nHead-to-head studies only\n</font></span>",
	"Brintellix_2690b88a6c": "<span style=\"font-family: &quot;1_WUORLG+AvenirNextLTPro-Bold&quot;; color: rgb(77, 127, 134);\"><font style=\"font-size: 15px;\">\nAcceptability (OR)\n</font></span>",
	"Brintellix_26ba4b5acb": "<span style=\"font-family: &quot;1_WUORLG+AvenirNextLTPro-Bold&quot;; color: rgb(77, 127, 134);\"><font style=\"font-size: 13px;\">\nEfficacy (OR)\n</font></span>",
	"Brintellix_261751aa37": "<span style=\"color: rgb(77, 127, 134); font-family: '15_VDWFON+AvenirNextLTPro-Demi';\"><font style=\"font-size: 22.5px;\">References</font></span>",
	"Brintellix_26e310d802": "<font style=\"font-size: 15px; font-family: '3_BNJCUB+AvenirNextLTPro-Regular';color: rgb(100, 94, 94);line-height: 1.3;display:inline-block;\"><b>\n1. </b>Cipriani A et al. Lancet 2018;391:1357-1366.\n</font>",
	"Brintellix_26825c1a0e": "",
	"Brintellix_26541d0e59": "Text",
	"Brintellix_265d184e9f": "<span style=\"color: rgb(77, 127, 134); font-family: '1_WUORLG+AvenirNextLTPro-Bold';\"><font style=\"font-size: 20px;\">\nHead-to-head studies only\n</font></span>",
	"Brintellix_26ebed0abf": "<span style=\"color: rgb(77, 127, 134); font-family: '1_WUORLG+AvenirNextLTPro-Bold';\"><font style=\"font-size: 15px;\">\nAcceptability (OR)\n</font></span>",
	"Brintellix_26f9f5cbf9": "<span style=\"color: rgb(77, 127, 134); font-family: '1_WUORLG+AvenirNextLTPro-Bold';\"><font style=\"font-size: 15px;\">\nEfficacy (OR)\n</font></span>",
	"Brintellix_266b708bba": "<font style=\"font-size: 17.5px; font-family: '3_BNJCUB+AvenirNextLTPro-Regular';color: rgb(100, 94, 94);line-height: 1.3;display:inline-block;\">\n522 trials, 116,477 patients and 21 antidepressants were analyzed in the acute treatment of adults with major depressive disorder\n</font>",
	"Brintellix_26a7892ef5": "<font style=\"font-size: 11.5px; font-family: '3_BNJCUB+AvenirNextLTPro-Regular';color: rgb(100, 94, 94);line-height: 1.3;display:inline-block;\">\n<p style=\"margin-bottom: 1px;margin-top: 5px;\">* Efficacy was defined by a reduction of ≥50% of the total score on a standarlized observer-rating scale for depression (HAM-D or MADRS).</p>\n<p style=\"margin-bottom: 1px;margin-top: 5px;\">** Acceptability was defined based on all-cause discontinuation of the treatments.\n</p>\n<p style=\"margin-bottom: 1px;margin-top: 5px;\">ORs=odds ratios. <b>1</b>=agomelatine.  <b>2</b>=amitriptyline. <b>3</b>=bupropion. <b>4</b>=citalopram. <b>5</b>=clomipramine. <b>7</b>=duloxetine. <b>8</b>=escitalopram. <br><b>9</b>=ﬂuoxetine. <b>10</b>=ﬂuvoxamine. <b>12</b>=milnacipran. <b>13</b>=mirtazapine. <b>14</b>=nefazodone. <b>15</b>=paroxetine. <b>16</b>=reboxetine. <b>17</b>=sertraline. <br><b>18</b>=trazodone. <b>19</b>=venlafaxine. <b>21</b>=Brintellix<sup>®</sup> (vortioxetine). A network meta-analysis of only head-to-head studies included a single <br>direct study comparison of Brintellix<sup>®</sup> (vortioxetine) at a dose of 10 mg/day and venlafaxine at a dose of 150 mg/day.\n</p>\n<p style=\"margin-bottom: 1px;margin-top: 5px;\">The error bars, indicating 95% credibility intervals, reﬂect limited data for Brintellix<sup>®</sup> (vortioxetine) in this network meta-analysis.</p>\n</font>",
	"Brintellix_26e0d7012e": "Text",
	"Brintellix_26972ca6b1": "Text",
	"Brintellix_26452f8c8f": "Text",
	"Brintellix_26638fa9f0": "Text",
	"Brintellix_2659626f32": "Text",
	"Brintellix_2632fd5a5b": "Text",
	"Brintellix_2671d4ca14": "<font style=\"font-size: 11px; font-family: '3_BNJCUB+AvenirNextLTPro-Regular';color: rgb(100, 94, 94);line-height: 1.3;display:inline-block;\">\n522 trials, 116,477 patients and 21 antidepressants were analyzed in the acute treatment of adults with major depressive disorder.\n<br>* Efficacy was defined by a reduction of ≥50% of the total score on a standarlized observer-rating scale for depression (HAM-D or MADRS); ** Acceptability was defined based\non all-cause discontinuation of the treatments. ORs=odds ratios. <b>1</b>=agomelatine. <b>2</b>=amitriptyline. <b>3</b>=bupropion. <b>4</b>=citalopram. <b>5</b>=clomipramine. <b>7</b>=duloxetine. <b>8</b>=escitalopram.\n<b>9</b>=ﬂuoxetine. <b>10</b>=ﬂuvoxamine. <b>12</b>=milnacipran. <b>13</b>=mirtazapine. <b>14</b>=nefazodone. <b>15</b>=paroxetine. <b>16</b>=reboxetine.<b> 17</b>=sertraline. <b>18</b>=trazodone. <b>19</b>=venlafaxine. <b>21</b>=Brintellix®\n(vortioxetine). A network meta-analysis of only head-to-head studies included a single direct study comparison of Brintellix® (vortioxetine) at a dose of 10 mg/day and venlafaxine\nat a dose of 150 mg/day. The error bars, indicating 95% credibility intervals, reﬂect limited data for Brintellix® (vortioxetine) in this network meta-analysis.\n</font>",
	"Brintellix_26132d2fb3": "<div style=\"font-family: serif;font-family: '2_VDWFON+AvenirNextLTPro-Demi';font-size: 13px;background-color: #e5f0f2;box-sizing: border-box;color: #4d7f86;\">\n\t<div style=\"float: left;text-align: center;border-left: 1px solid #fff;padding: 12px 17px;line-height:1.3;background-color: #e5f0f2;\">MADRS 10</div>\n\t<div style=\"float: left;text-align: center;border-left: 1px solid #fff;padding: 12px 17px;line-height:1.3;background-color: #e5f0f2;\">Physical symptoms</div>\n\t<div style=\"float: left;text-align: center;border-left: 1px solid #fff;padding: 12px 17px;line-height:1.3;background-color: #e5f0f2;\">Remission</div>\n\t<div style=\"float: left;text-align: center;border-left: 1px solid #fff;padding: 12px 17px;line-height:1.3;background-color: #e5f0f2;\">Relapse prevention</div>\n\t<div style=\"float: left;text-align: center;border-left: 1px solid #fff;padding: 12px 17px;line-height:1.3;background-color: #e5f0f2;\">Short term</div>\n\t<div style=\"float: left;text-align: center;border-left: 1px solid #fff;padding: 12px 17px;line-height:1.3;background-color: #e5f0f2;\">Long term</div>\n\t<div style=\"float: left;text-align: center;border-left: 1px solid #fff;padding: 12px 17px;line-height:1.3;background-color: #e5f0f2;color: #fff;background: rgb(233,90,0);background: linear-gradient(90deg, rgba(233,90,0,1) 0%, rgba(240,125,0,1) 100%);background: -webkit-linear-gradient(90deg, rgba(233,90,0,1) 0%, rgba(240,125,0,1) 100%);\">Meta-analysis</div>\n\t<div style=\"float: left;text-align: center;border-left: 1px solid #fff;padding: 4px 12px 3px;line-height:1.3;background-color: #e5f0f2;\">Suboptimal responses<br>to SSRI/SNRI</div>\n</div>",
	"Brintellix_26109090a8": "Text"
}
